Details

Autor(en) / Beteiligte

• Chan, H. L.‐Y.
• Wong, V. W.‐S.
• Chim, A. M.‐L.
• Chan, H.‐Y.
• Wong, G. L.‐H.
• Sung, J. J.‐Y.

Titel

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

Ist Teil von

• Alimentary pharmacology & therapeutics, 2010-12, Vol.32 (11‐12), p.1323-1331

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2010

Link zum Volltext

Quelle

Wiley Blackwell Single Titles

Beschreibungen/Notizen

• Aliment Pharmacol Ther 2010; 32: 1323–1331 Summary Background  On‐treatment predictors of response to peginterferon can guide individualization of therapy in chronic hepatitis B virus infection. Aim  To investigate the use of serum hepatitis B surface antigen quantification to predict sustained response. Methods  Hepatitis B e antigen‐positive chronic hepatitis B patients who received peginterferon for 32–48 weeks with or without lamivudine combination were studied. Sustained response was defined as hepatitis B e antigen seroconversion and chronic hepatitis B virus DNA <10 000 copies/mL until 12 months post‐treatment. Results  Twenty‐one of 92 (23%) patients achieved sustained response. At month 6, the area under receiver operating characteristics curve for hepatitis B surface antigen to predict sustained response was 0.77 (95% confidence interval 0.65–0.89, P < 0.001). An hepatitis B surface antigen cutoff at 300 IU/mL at month 6 could give the maximum combination of sensitivity (62%) and specificity (89%) to predict sustained response. Nine of 21 (43%) sustained responders vs. 9 of 71 (13%) nonsustained responders had >1 log hepatitis B surface antigen reduction at month 6 (P < 0.001). Combined hepatitis B surface antigen ≤300 IU/mL and >1 log reduction at month 6 had sensitivity, specificity, positive and negative predictive values of 43%, 96%, 75% and 85% to predict sustained response, respectively. Conclusion  On‐treatment serum hepatitis B surface antigen can predict response to peginterferon therapy in chronic hepatitis B.